Immediate Reports All 2019 2020 2021 2022 Results of General Meeting held on Nov 8, 2022 CD’X (about 5.5%) received approval from an American health insurer to cover the use of IsoPSA for the early diagnosis of prostate cancer Calling of Annual Meeting for Nov 8, 2022 Nerview (7.63%) will invest 300 A$ in Medipress against an allocation of about 3.27% in Medipress Ocon Medical’s engagement (approximately 10%) in understandings for licensing and business cooperation with a Chinese pharma company Negotiations for the merger agreement ended without it maturing into a binding agreement Memorandum of Understanding does not require licensing and cooperation between Okon Medical (10.2%) and Chinese Pharma An update in connection with non-memorandum of understanding negotiations does not require the merger of one of the portfolio companies E.F.A (held approximately 7.68%) in an investment round of up to $ 3.65 million, the company will participate in approximately $ 100 million Results of General Meeting held on Dec 28, 2021 Calling of Annual Meeting for Dec 28, 2021 One of the portfolio companies in the negotiations does not require a merger against cash consideration contingent on objectives, impact on revenues, equity and cash in the company’s reports Cardiacsense (c. 5.18%) – in an investment round of about $ 10 million In a binding distribution agreement with CD’X (held approximately 5.5%) you will receive exclusivity to market CD’X products Cardiacsense (about 5.55%) – Completion of processing of experimental results of the medical watch Cardiacsense2, E.F.A experimental results for white blood cell counts using the RevDx device Cardiacsense (approximately 5.57%), in an exclusive distribution agreement in Brazil for the sale of medical watches to detect heart rhythm disorders – correction of the company’s holding rate Ora Air has completed an IPO on the Tel Aviv Stock Exchange, the company holds after 1.83% Cardiacsence (approximately 5.93%), in an exclusive distribution agreement in Brazil for a number of medical watches for the detection of arrhythmias Nervio (approximately 8.6%) has completed a milestone in an investment agreement, will transfer to Nervio a second payment in the amount of NIS 200 Results of General Meeting held of May 9, 2021 A meeting convened on 2.5.21 is adjourned to 9.5.21 The portfolio company Aura Smart Air (2.4%) submitted the first draft prospectus for the issue based on reports on 31.12.20 A meeting convened on 18.4.21 is postponed to 2.5.21 Letter from the company’s CEO to shareholders Cardiacsense (held approximately 5.94%) submitted the first draft of a prospectus for a public offering on the stock exchange Calling of Special Meeting for Apr 18, 2021 Approval of granting a one-time grant at the discretion of the Company’s CEO Cardiacsense (approximately 5.67%), Receives CE approval for the marketing of a medical watch that it opened in Europe, expected date for FDA approval The investment of $ 150k as part of an investment round of about $ 17k in CDX according to about $ 112k (after), will hold 6.64% A round of fundraising in Cardiacsense (about 5.8%) – the debtor will invest $ 250, hold about 5.95% of the capital, B. Control will participate EFA (approximately 7.9%), began an experiment in collaboration with Maccabi and the Medical Campus to validate the data reported by the RevDx device developed by it Results of general meeting Update call details and telephone conference for the special general meeting to be held today (19.1.21) Ora Air (approx. 1.93%) in an exclusive distribution agreement for its products in Taiwan and Vietnam Binding investment agreement with Ocon Medical, the company will invest $ 350m in an investment round of about $ 1.5m in exchange for an allocation from Ocon Medical. Nervio investment agreement signed, will invest up to NIS 650,000 against 6% in Nervio, an option for additional investment Calling of Special meeting for Jun 19, 2021 Cardiacsense (about 5.67%) – Estimated deadlines for receiving CE and FDA approvals for the medical watch TrainPain (approximately 5.69%) – The trial results of the treatment using the digital platform for people suffering from fibromyalgia syndrome in Belgium Cardiacsense (about 5.67%) began an experiment to prove the effectiveness of the smartwatch it developed in measuring continuous breathing rate The Memorandum of Understanding does not require an investment of up to NIS 650,000 in Nervio against the allotment of shares The memorandum of understanding does not require an investment of up to $ 350m in Okon Medical as part of a $ 1.5m round of funding Ora Smart (approximately 1.93%), has signed a distribution agreement for the sale of its products in China Results of general meeting Cardiacsence (about 5.67%) – completed the first phase of an experiment to measure respiratory rate Calling of Annual & special meeting for Oct 14, 2020 – Update Astellas (about 0.6%) – announced the cancellation of the agreement with Juventas Cardiacsense (5.67%), has signed an exclusive distribution agreement for the sale of medical watches in the UAE Calling of Annual & special meeting for Oct 14, 2020 Cardiacsense (about 5.67%) has signed an exclusive distribution agreement for the sale of medical watches in Switzerland TrainPain (about 5.69%) – Beginning of an experiment for treatment using the AI-based digital platform Invest $ 250,000 in Ora Smart as part of an investment round of $ 3m according to $ 10m (before) – following the reports Receiving additional consideration for a merger transaction between Remedy (9%) with Optimize Results of general meeting Invest $ 100 in a fundraising round at E.F.A, hold after 8.15% Cardiacsense (5.67%) received a medical certificate for medical clock for heart rate monitoring and diagnosis of atrial fibrillation Memorandum of Understanding for the investment of $ 250,000 in Ora Air (engaged in air quality), against 1.93% in Ora Air Calling of special meeting of Aug 20, 2020 Continues to negotiate a binding agreement for a business partnership with CD’X CD’X (held 7%) began commercial-marketing OISPSA test for the Cleveland Clinic Urology Department Cardiacsense (approx. 5.87%) – Starting an Experiment on the Smart Watch for Breathing Rhythm at Ichilov Hospital Cardiacsense Capital Raising Round (5.33%) – The Company Will Invest $ 250, Hold 5.87% of Equity Result of general meeting Cardiacsense has signed an exclusive distribution agreement Cardiacsence (approximately 6.16%) in exclusive distribution agreement for medical watches it develops Cardiacsense (6.16%), has signed an exclusive distribution deal to sell medical watches Cardiacsense (6.34%), signed two exclusive distribution agreements for the sale of medical watches IFA (9.09%), has received the right to grant permission from the Innovation Authority for the R&D project for a mobile blood test device Cardiacsense (6.34%) – Positive Clinical Trial Clinical Trial Detection for Cardiac Disorders Result of general meeting Calling of general & special meeting for June 7, 2020 Cardiacsense (about 6.34%), signed an exclusive distribution agreement for distributing medical watches in Australia and New Zealand Subsidiary (approximately 6.34%), in an exclusive distribution agreement in South Africa for the sale of medical watches for the detection of cardiac arrhythmias A meeting convened on April 26, 2020 is adjourned on May 3, 2020 Memorandum of Understanding (7.97%) CD’X will provide exclusive marketing and diagnostic testing for prostate cancer diagnosis A meeting convened for 6.4.20 is adjourned for 26.4.20 discussion with shareholders of a company Merhavia has signed an agreement to cancel an option to buy Liventhal shares Extends on the date of the 2019 Periodic Report The court ordered the transfer of part of the proceeds from the sale of a property in Bat Shlomo to the company Calling for general meeting of Apr 6, 2020 Cardiacsense (7.58%), Signs First Distribution Agreement for the Sale of Medical Watches in South America, $ 1.5 Million for 3 Years Calling of spicial meeting for Apr, 6 2020 Board of Directors Approves Company Participation in Recruitment Rounds at Company Holds CD’X and Cardiacsense Court decision, settlement / compromise / proceedings Results of general meeting Results of meeting of Nov 5, 2019 CDX (held about 7.5%) FDA approval to test for prostate cancer as a breakthrough device Calling of meeting for Nov 13, 2019 A meeting convened for October 6, 2019 , is adjourned for November 5, 2019, in light of the company’s request Remedy (about 9.45%) has completed an inverted triple merger agreement with OptimizerX Calling of special meeting for Oct 6, 2019 RMDY (about 6%) in merger agreement with OPTIMIZERX for cash and OPTIMIZERX shares, $ 1.1-3.7m External Investor Investments Closes $ 3 Million in Cleveland Diagnostics against Shares in Up to $ 6 Million The Company’s Board of Directors has approved a dividend distribution policy Decided not to pursue investment negotiations with Spectra Kan The transaction for investment in Violi – Debt cannabis was completed CD’X (about 7.85%) in understandings with investors investing $ 3m against shares in a round of up to $ 6m, reflecting a value of $ 65m Non-binding letter of intent to sell RMDY (held -6%) CD’X (approximately 7.85%) – Promotes Trials for FDA Application for Prostate Cancer Diagnostic Product
CD’X (about 5.5%) received approval from an American health insurer to cover the use of IsoPSA for the early diagnosis of prostate cancer
Ocon Medical’s engagement (approximately 10%) in understandings for licensing and business cooperation with a Chinese pharma company
Memorandum of Understanding does not require licensing and cooperation between Okon Medical (10.2%) and Chinese Pharma
An update in connection with non-memorandum of understanding negotiations does not require the merger of one of the portfolio companies
E.F.A (held approximately 7.68%) in an investment round of up to $ 3.65 million, the company will participate in approximately $ 100 million
One of the portfolio companies in the negotiations does not require a merger against cash consideration contingent on objectives, impact on revenues, equity and cash in the company’s reports
In a binding distribution agreement with CD’X (held approximately 5.5%) you will receive exclusivity to market CD’X products
Cardiacsense (about 5.55%) – Completion of processing of experimental results of the medical watch Cardiacsense2,
Cardiacsense (approximately 5.57%), in an exclusive distribution agreement in Brazil for the sale of medical watches to detect heart rhythm disorders – correction of the company’s holding rate
Cardiacsence (approximately 5.93%), in an exclusive distribution agreement in Brazil for a number of medical watches for the detection of arrhythmias
Nervio (approximately 8.6%) has completed a milestone in an investment agreement, will transfer to Nervio a second payment in the amount of NIS 200
The portfolio company Aura Smart Air (2.4%) submitted the first draft prospectus for the issue based on reports on 31.12.20
Cardiacsense (held approximately 5.94%) submitted the first draft of a prospectus for a public offering on the stock exchange
Cardiacsense (approximately 5.67%), Receives CE approval for the marketing of a medical watch that it opened in Europe, expected date for FDA approval
The investment of $ 150k as part of an investment round of about $ 17k in CDX according to about $ 112k (after), will hold 6.64%
A round of fundraising in Cardiacsense (about 5.8%) – the debtor will invest $ 250, hold about 5.95% of the capital, B. Control will participate
EFA (approximately 7.9%), began an experiment in collaboration with Maccabi and the Medical Campus to validate the data reported by the RevDx device developed by it
Update call details and telephone conference for the special general meeting to be held today (19.1.21)
Ora Air (approx. 1.93%) in an exclusive distribution agreement for its products in Taiwan and Vietnam
Binding investment agreement with Ocon Medical, the company will invest $ 350m in an investment round of about $ 1.5m in exchange for an allocation from Ocon Medical.
Nervio investment agreement signed, will invest up to NIS 650,000 against 6% in Nervio, an option for additional investment
Cardiacsense (about 5.67%) – Estimated deadlines for receiving CE and FDA approvals for the medical watch
TrainPain (approximately 5.69%) – The trial results of the treatment using the digital platform for people suffering from fibromyalgia syndrome in Belgium
Cardiacsense (about 5.67%) began an experiment to prove the effectiveness of the smartwatch it developed in measuring continuous breathing rate
The Memorandum of Understanding does not require an investment of up to NIS 650,000 in Nervio against the allotment of shares
The memorandum of understanding does not require an investment of up to $ 350m in Okon Medical as part of a $ 1.5m round of funding
Ora Smart (approximately 1.93%), has signed a distribution agreement for the sale of its products in China
Cardiacsense (5.67%), has signed an exclusive distribution agreement for the sale of medical watches in the UAE
Cardiacsense (about 5.67%) has signed an exclusive distribution agreement for the sale of medical watches in Switzerland
TrainPain (about 5.69%) – Beginning of an experiment for treatment using the AI-based digital platform
Invest $ 250,000 in Ora Smart as part of an investment round of $ 3m according to $ 10m (before) – following the reports
Cardiacsense (5.67%) received a medical certificate for medical clock for heart rate monitoring and diagnosis of atrial fibrillation
Memorandum of Understanding for the investment of $ 250,000 in Ora Air (engaged in air quality), against 1.93% in Ora Air
Cardiacsense (approx. 5.87%) – Starting an Experiment on the Smart Watch for Breathing Rhythm at Ichilov Hospital
Cardiacsence (approximately 6.16%) in exclusive distribution agreement for medical watches it develops
IFA (9.09%), has received the right to grant permission from the Innovation Authority for the R&D project for a mobile blood test device
Cardiacsense (about 6.34%), signed an exclusive distribution agreement for distributing medical watches in Australia and New Zealand
Subsidiary (approximately 6.34%), in an exclusive distribution agreement in South Africa for the sale of medical watches for the detection of cardiac arrhythmias
Memorandum of Understanding (7.97%) CD’X will provide exclusive marketing and diagnostic testing for prostate cancer diagnosis
The court ordered the transfer of part of the proceeds from the sale of a property in Bat Shlomo to the company
Cardiacsense (7.58%), Signs First Distribution Agreement for the Sale of Medical Watches in South America, $ 1.5 Million for 3 Years
Board of Directors Approves Company Participation in Recruitment Rounds at Company Holds CD’X and Cardiacsense
A meeting convened for October 6, 2019 , is adjourned for November 5, 2019, in light of the company’s request
External Investor Investments Closes $ 3 Million in Cleveland Diagnostics against Shares in Up to $ 6 Million
CD’X (about 7.85%) in understandings with investors investing $ 3m against shares in a round of up to $ 6m, reflecting a value of $ 65m
CD’X (approximately 7.85%) – Promotes Trials for FDA Application for Prostate Cancer Diagnostic Product
